C2 Pharma (C2P) has expanded their advisory board with a new member. The Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group’s board consists of well-respected pharmaceutical industry experts that provides strategic guidance on the progress and growth of the company via organic and M&A activities in the mid and long-term.
“The C2P advisory board now includes Jim Miller, who joins existing members Dr Uwe Böhlke, Joachim Roeser, and Dr Jürgen Sackhoff,” said Andrew Badrot, CEO of C2 PHARMA “We are thrilled to expand our advisory board and align to gain their insight as we grow into a premier ophthalmic and niche active pharmaceutical ingredient (API) supplier with a unique virtual manufacturing model. The prowess each member brings to the board is invaluable in creating sustainable growth, while making a clear mark on this industry.”
Jim Miller founded PharmSource, a pioneering online database for contract manufacturing intelligence now run by Global Data. He is regarded as a biopharmaceutical contract manufacturing and development sector expert and is a frequent contributor to industry publications and events, as well as working as a consultant and a member of the Board of Advisors of C2P.
Böhlke is a leading executive manager and board member for companies across the chemicals, pharmaceuticals and polymers industries. Today, he is the chief operating officer (COO) at REHAU. A former member of the executive board at Lonza, and Oerlikon Surface Solutions AG, since 2014 he has been a member of the Board of Advisors of C2P.
Roeser has vast experience in business development and executive management for the chemicals, material science and polymers industries. Formerly, he held CEO and president positions for Amber Chemical Group, Luzenac and Ferro Group. Today he is the board director for Innospec, in addition to his role as a member of the Board of Advisors of C2 PHARMA.
Sackhoff is a distinguished professional with a diverse executive and legal background. He spent more than 3 years as CEO at SGD Pharma, with a history of 14 years at Schott AG ending as Executive Vice President of Pharmaceutical Systems, and nearly a decade of General Counsel and legal work with Henkel Corporation and Generali. In 2018, he branched into independent executive consultation, legal and board work, including joining as a member of the Board of Advisors of C2P.
